p-Anisic Acid for Health & Longevity

Created on 11/14/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

p-Anisic acid, a plant acid from anise used mainly as a flavoring and skin-care preservative, is not sold as a health supplement. Every proposed benefit (blood sugar control, inflammation, brain chemistry, skin pigment) rests on laboratory or animal work; none has been tested in people. Deliberate higher intake has never been studied, and people with reduced kidney function clear it much more slowly. Its value remains unknown. (Full Review)

Protocol

Experimental oral doses
None tested in humans
Diabetic rats received 25, 50 or 100 mg/kg for four weeks; no human-equivalent dose validated
Dietary exposure
1 mg anethole daily
Close to daily dietary intake; 50 mg in a normal measure of anise-flavored beverage
Topical approach
0.042–0.16%
Range in infant cosmetics; a self-preserving system used 0.1%
Time to effect
Blood Sugar and Insulin Support
Unknown in humans
Rat glucose effects were assessed after four weeks of dosing

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Severely reduced kidney function (creatinine clearance 20–30 mL/min or lower)
  • Insulin- or sulfonylurea-treated diabetes with past hypoglycemia
Key Interactions
  • Aniracetam (a memory drug)
  • Anethole-rich foods and oils (anise, star anise, fennel)
Theoretical (inferred from mechanism)
  • Glucose-lowering drugs (insulin, glipizide, glimepiride, metformin)
  • Glucose-lowering supplements (berberine, cinnamon extract, chromium)
  • Salicylates and benzoates (aspirin, salsalate, sodium benzoate)
  • Topical tyrosinase inhibitors (hydroquinone, kojic acid, arbutin)
  • Prolonged fasting or very-low-carbohydrate diets

Risk & Side Effects

  • High:
  • Medium:
  • Low: Slower clearance with reduced kidney function
  • Speculative: Additive blood sugar lowering; uneven skin lightening with topical use; altered brain signaling

Monitoring

Marker Target Why
Fasting plasma glucose Below 100 mg/dL Rat data suggest lowering; hypoglycemia safety check
HbA1c Below 5.7% Sustained glucose effect
Serum creatinine Men 0.74–1.35 mg/dL; women 0.59–1.04 mg/dL Safety check: rising values signal slower clearance
eGFR Not specified in the ER Baseline kidney function

Cadence: Baseline fasting glucose, HbA1c and serum creatinine with eGFR, morning draw after an overnight fast; fasting glucose at 2 and 4 weeks, then HbA1c and serum creatinine every 3 months while use continues; with glucose-lowering drugs, home glucose checks once or twice daily during the first 2 weeks.

Qualitative Assessment

  • Skin tone at topical application sites (uneven lightening)
  • Shakiness, sweating or confusion between meals (possible low blood sugar)
  • Mood, anxiety level and mental alertness
  • Digestive comfort after oral intake